Search for: "Mylan LLC" Results 121 - 140 of 266
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
30 Dec 2021, 12:03 pm by Linda C. Severin
 The case, originally brought by a client of the Whistleblower Law Collaborative LLC  alleged fraud against Medicaid and Medicare patients. [read post]
28 Sep 2010, 3:14 pm by Kelly
(Patent Docs) Herceptin (Trastuzumab) – US: Patent infringement complaint: GlaxoSmithKline LLC v. [read post]
5 Oct 2020, 10:25 am by Dennis Crouch
Mylan Pharmaceuticals Inc., No. 19-1451; Arthrex, Inc. v. [read post]
28 Sep 2016, 8:39 am by Dennis Crouch
The final new petition is a personal jurisdiction case: Mylan v. [read post]
27 Jun 2011, 8:41 am by Kali Borkoski
Amicus brief of Mylan Pharmaceuticals, Inc. [read post]
24 Oct 2016, 2:35 am
While this moggy was struggling to get back from Indonesia, the Court of Appeal handed down its decision in the pregabalin appeal Warner-Lambert Company LLC v Generics (UK) Ltd (t/a Mylan) & Ors [2016] EWCA Civ 1006 (13 October 2016), and finally the IPKat has managed to blog about it (the lateness by no means reflecting on the importance of the judgment).It is very much a judgment of three halves.In the first part of the judgment (up to [135]), which substantively… [read post]
20 Jan 2016, 8:00 am by Dennis Crouch
Apotex Inc., No. 15-281 Mylan Pharmaceuticals Inc. v. [read post]
1 Jan 2016, 9:00 am by Dennis Crouch
Apotex Inc., No. 15-281 Mylan Pharmaceuticals Inc. v. [read post]
12 Jan 2016, 11:39 am by Dennis Crouch
Apotex Inc., No. 15-281 Mylan Pharmaceuticals Inc. v. [read post]
16 May 2023, 10:50 am by Kelly Shivery
 Among the firm’s many successes are the Mallinckrodt and Mylan cases discussed above. [read post]
27 Apr 2010, 10:58 pm
US: MPEG LA announces formation of gene patent pool (Patent Docs) US: In an amended complaint, plaintiff adds count of false marking where defendants allegedly marked products with plaintiff’s patent number: Tripharma LLC v. [read post]
28 Mar 2022, 7:13 am by Linda C. Severin
Landolt came to us with his concerns, we immediately recognized the significance of this matter because our firm had handled the Mylan EpiPen rebate case,” Severin said, referring to a 2016 case where Mylan paid $465 million for misclassifying the emergency allergy EpiPen shot as a generic drug to avoid paying the higher rebates. [read post]